Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
What are the prior authorization requirementsBMI, comorbidities, weight management program
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
Pharmacist Note Discuss all medications, supplements and health conditions with the healthcare provider before beginning GLP-1 treatment
Crider, C
US$ 23.27
US$ 28.23
US$ 28.78
US$ 27.99
US$ 22.05
